Core Viewpoint - Innovent Biologics and Jiangsu Aosaikang Pharmaceutical have entered a strategic collaboration for limertinib, a third-generation EGFR TKI for lung cancer treatment, with Innovent obtaining exclusive commercialization rights in mainland China [1][2][4]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various diseases, including oncology [8]. - Jiangsu Aosaikang Pharmaceutical Co. Ltd. specializes in innovative research and development in oncology and other therapeutic areas, with a strong emphasis on small-molecule targeted drugs and biologics [10][11]. Product Details - Limertinib is an orally administered, third-generation EGFR TKI, currently under review by China's National Drug Administration for two indications related to NSCLC [2][6]. - The drug targets adult patients with specific EGFR mutations, which are prevalent in the Chinese population, addressing a significant medical need [5][6]. Clinical Trial Results - A Phase 3 clinical trial comparing limertinib to gefitinib met its primary endpoint, with results expected to be presented at future academic conferences [3][7]. Strategic Collaboration - Under the agreement, Innovent will receive a commercialization service fee based on net sales, while ASK Pharm will handle production and supply, along with receiving milestone payments [2][4]. - Both companies aim to leverage their strengths to enhance the accessibility and effectiveness of lung cancer treatments in China [4][11].
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer